Michael Clemens

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

Medicine, Immunology, Oncology +7

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

Bella Kaufman, John R. Mackey, Michael Clemens et al. · Journal of Clinical Oncology · 2009 · 850 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk et al. · The Lancet Oncology · 2016 · 739 citations

Medicine, Oncology, Pharmacology +16

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

Gϋnter von Minckwitz, Andreas du Bois, Marcus Schmidt et al. · Journal of Clinical Oncology · 2009 · 689 citations

Medicine, Oncology, Pharmacotherapy +17